Search research articles
Contact Us
Filters
Showing results (101-110 of 501) with videos related to
Page
of 51
Sort By:
Current Opinion in Nephrology and Hypertension
|
January 5, 2021
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum
Kulanka H Premachandra, Richard O Day, Darren M Roberts
Inflammopharmacology
|
September 17, 2021
Honorary Professor Garry Graham
Richard O Day, Kenneth M Williams, Kieran F Scott
The American Journal of Emergency Medicine
|
February 28, 2026
Ending routine opioid use for acute non-specific back pain
Pippa Flanagan, Martin Underwood, Richard O Day, et al.
The Medical Journal of Australia
|
May 16, 2002
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors
John P Edmonds, Richard O Day, James V Bertouch
Drugs
|
February 5, 2004
[Tolerability of paracetamol]
Garry G Graham, Kieran F Scott, Richard O Day
Internal Medicine Journal
|
January 18, 2006
Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?
C Y Lu, K M Williams, R O Day
Current Pharmaceutical Design
|
April 12, 2002
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)
Garry G Graham, Robert I Graham, Richard O Day
Clinical Pharmacokinetics
|
May 1, 1983
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates
R O Day, D D Shen, D L Azarnoff
Australia and New Zealand Health Policy
|
March 3, 2007
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines
Christine Y Lu, Kenneth M Williams, Richard O Day
British Journal of Clinical Pharmacology
|
August 1, 1991
1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect
D J Birkett, J O Miners, R O Day
Page
of 51
Search research articles
Search
Showing results (101-110 of 501) with videos related to
Sort By:
Page
of 51
Current Opinion in Nephrology and Hypertension
|
January 5, 2021
Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum
Kulanka H Premachandra, Richard O Day, Darren M Roberts
Inflammopharmacology
|
September 17, 2021
Honorary Professor Garry Graham
Richard O Day, Kenneth M Williams, Kieran F Scott
The American Journal of Emergency Medicine
|
February 28, 2026
Ending routine opioid use for acute non-specific back pain
Pippa Flanagan, Martin Underwood, Richard O Day, et al.
The Medical Journal of Australia
|
May 16, 2002
The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors
John P Edmonds, Richard O Day, James V Bertouch
Drugs
|
February 5, 2004
[Tolerability of paracetamol]
Garry G Graham, Kieran F Scott, Richard O Day
Internal Medicine Journal
|
January 18, 2006
Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?
C Y Lu, K M Williams, R O Day
Current Pharmaceutical Design
|
April 12, 2002
Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)
Garry G Graham, Robert I Graham, Richard O Day
Clinical Pharmacokinetics
|
May 1, 1983
Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates
R O Day, D D Shen, D L Azarnoff
Australia and New Zealand Health Policy
|
March 3, 2007
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines
Christine Y Lu, Kenneth M Williams, Richard O Day
British Journal of Clinical Pharmacology
|
August 1, 1991
1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect
D J Birkett, J O Miners, R O Day
Page
of 51